Emergent BioSolutions Inc.

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:03 2026-02-13 pm EST			5-day change	1st Jan Change
10.83 ^USD	-0.18%		-0.82%	-12.38%

Feb. 13	Emergent BioSolutions Says FDA Approves Supplemental NDA for Nasal Spray Product	MT
Feb. 13	Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application for NARCAN® Nasal Spray Multipacks	CI

Sector Update: Health Care Stocks Softer in Afternoon Trading

Published on 01/15/2026 at 01:53 pm EST

MT Newswires

Latest news about Emergent BioSolutions Inc.

Feb. 13	Emergent BioSolutions Says FDA Approves Supplemental NDA for Nasal Spray Product	MT
Feb. 13	Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application for NARCAN® Nasal Spray Multipacks	CI
Feb. 12	Emergent BioSolutions Gets FDA Greenlight for Multipacks of Narcan	DJ
Jan. 16	Powell Investigation Upends Final Stretch of Fed Chair Contest	DJ
Jan. 15	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Jan. 15	Top Midday Decliners	MT
Jan. 15	Emergent announces resolution of New York attorney general investigation	RE
Jan. 15	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT
Jan. 15	Ex-CEO sued by New York for insider trading tied to COVID vaccine contamination	RE
Jan. 15	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update	DJ
Jan. 15	Emergent BioSolutions' Former CEO Sued for Insider Trading by New York Attorney General	MT
Jan. 15	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading	DJ
Jan. 14	Emergent BioSolutions Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM
Jan. 14	Emergent Biosolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN Nasal Spray to Be Packaged in A New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness	CI
Jan. 14	Emergent BioSolutions Says US FDA Approves sNDA for New Packaging for Narcan Nasal Spray	MT

Chart Emergent BioSolutions Inc.

Duration

Period

EBS: Dynamic Chart

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Employees

900

Sector

Pharmaceuticals

Calendar

Feb. 25 - Q4 2025 Earnings Release

More about the company